Incidence of Contrast-Induced Nephropathy in Patients With Multiple Myeloma Undergoing Contrast-Enhanced CT

被引:33
|
作者
Pahade, Jay K. [1 ]
LeBedis, Christina A. [1 ]
Raptopoulos, Vassilios D. [1 ]
Avigan, David E. [2 ]
Yam, Chun S. [1 ]
Kruskal, Jonathan B. [1 ]
Pedrosa, Ivan [1 ]
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Radiol, Sch Med, Boston, MA 02215 USA
[2] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Hematol Oncol, Sch Med, Boston, MA 02215 USA
关键词
contrast-induced nephropathy; multiple myeloma; ACUTE-RENAL-FAILURE; INDUCED NEPHROTOXICITY; RISK; INSUFFICIENCY; PATHOGENESIS; IODIXANOL; COHORT;
D O I
10.2214/AJR.10.5152
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. The purpose of this article is to evaluate the incidence of contrast-induced nephropathy (CIN) and the effects of associated risk factors in patients with multiple myeloma undergoing contrast-enhanced CT (CECT) with IV administration of nonionic iodinated contrast agent. MATERIALS AND METHODS. This retrospective review of medical records identified patients with a diagnosis of myeloma who underwent a CECT examination of the chest, abdomen, or pelvis between January 1, 2005, and December 1, 2008. Analysis for CIN, as defined by an increase in creatinine level after the CECT examination of 25% or more, or of 0.5 mg/dL, compared with the level before the CECT examination, both within 48 hours and within 7 days, was performed. Statistical correlations between the development of CIN and creatinine level before CECT examination, patient location, type and amount of contrast agent, blood urea nitrogen-creatinine ratio, history of diabetes, hypercalcemia, Bence Jones proteinuria, beta(2)-microglobulin level, albumin level, International Myeloma Staging System stage, and history of myeloma provided at the time the CT examination was ordered were calculated. RESULTS. Forty-six patients who completed 80 unique examinations were included; their average creatinine level before CECT examination was 0.97 mg/dL. There was no significant difference in the average creatinine levels before CT examination between patients without and those with CIN. Four (5%) and 12 (15%) patients developed CIN within 48 hours and 7 days, respectively. Only serum beta(2)-microglobulin level showed a statistically significant (p = 0.03) correlation with the development of CIN. CONCLUSION. The incidence of CIN in patients with multiple myeloma with a normal creatinine level is low and correlates with beta(2) -microglobulin levels. The administration of contrast agent in this patient population is safe but should be based on the potential benefit of the examination and the expected low risk of developing CIN.
引用
收藏
页码:1094 / 1101
页数:8
相关论文
共 50 条
  • [1] Incidence of Contrast-Induced Nephropathy in Patients with Multiple Myeloma Undergoing Contrast-Enhanced Procedures
    Crowley, Maeve P.
    Prabhakaran, Vinitha N.
    Gilligan, Oonagh M.
    PATHOLOGY & ONCOLOGY RESEARCH, 2018, 24 (04) : 915 - 919
  • [2] Contrast-induced nephropathy in patients with renal insufficiency undergoing contrast-enhanced MDCT
    Ryusuke Murakami
    Hiromitsu Hayashi
    Ken-ichi Sugizaki
    Tamiko Yoshida
    Emi Okazaki
    Shin-ichiro Kumita
    Chojin Owan
    European Radiology, 2012, 22 : 2147 - 2152
  • [3] Contrast-induced nephropathy in patients with renal insufficiency undergoing contrast-enhanced MDCT
    Murakami, Ryusuke
    Hayashi, Hiromitsu
    Sugizaki, Ken-ichi
    Yoshida, Tamiko
    Okazaki, Emi
    Kumita, Shin-ichiro
    Owan, Chojin
    EUROPEAN RADIOLOGY, 2012, 22 (10) : 2147 - 2152
  • [4] Contrast-induced nephropathy in patients with active cancer undergoing contrast-enhanced computed tomography
    Hong, Seok-In
    Ahn, Shin
    Lee, Yoon-Seon
    Kim, Won Young
    Lim, Kyung Soo
    Lee, Jae Ho
    Lee, Jae-Lyun
    SUPPORTIVE CARE IN CANCER, 2016, 24 (03) : 1011 - 1017
  • [5] Contrast-induced nephropathy in patients with active cancer undergoing contrast-enhanced computed tomography
    Seok-In Hong
    Shin Ahn
    Yoon-Seon Lee
    Won Young Kim
    Kyung Soo Lim
    Jae Ho Lee
    Jae-Lyun Lee
    Supportive Care in Cancer, 2016, 24 : 1011 - 1017
  • [6] Anemia and the risk of contrast-induced nephropathy in patients with renal insufficiency undergoing contrast-enhanced MDCT
    Murakami, Ryusuke
    Kumita, Shin-ichiro
    Hayashi, Hiromitsu
    Sugizaki, Ken-ichi
    Okazaki, Emi
    Kiriyama, Tomonari
    Hakozaki, Kenta
    Tani, Hitomi
    Miki, Izumi
    Takeda, Minako
    EUROPEAN JOURNAL OF RADIOLOGY, 2013, 82 (10) : E521 - E524
  • [7] Rates of Contrast-induced Nephropathy After Contrast-enhanced CT in Patients with Chronic Renal Insufficiency
    Petroziello, M.
    Klippenstein, D.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2007, 188 (05)
  • [8] Intravenous album in for the prevention of contrast-induced nephropathy in patients with liver cirrhosis and chronic kidney disease undergoing contrast-enhanced CT
    Choi, Heejung
    Kim, Yoonjung
    Kim, Soo Min
    Shin, Junam
    Jang, Hye Ryoun
    Lee, Jung Eun
    Huh, Wooseong
    Kim, Yoon-Goo
    Oh, Ha Young
    Kim, Dae Joong
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2012, 31 (02) : 106 - 111
  • [9] Incidence of Contrast-Induced Nephropathy after Contrast-Enhanced Computed Tomography in the Outpatient Setting
    Mitchell, Alice M.
    Jones, Alan E.
    Tumlin, James A.
    Kline, Jeffrey A.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (01): : 4 - 9
  • [10] The incidence of contrast-induced nephropathy with lomeprol is similar to the incidence of contrast-induced nephropathy with lopamidol
    Abe, Mitsuru
    Kimura, Takeshi
    Nakagawa, Yoshihisa
    Furukawa, Yutaka
    Akao, Masaharu
    Toma, Masanao
    Tamura, Toshihiro
    Taniguchi, Ryoji
    Hoshino, Kozo
    Suyama, Tamaki
    Imai, Masao
    Morimoto, Takeshi
    Kita, Toru
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 9B - 9B